Page 9 - emap_newsletter_V2

eMAP – electronic EHA Medical HemAtology Program

A group comparison between not eligible and eligible patients identified median years from diagnosis, International Staging
System (ISS) III, ECOG >1, renal impairment, anemia, thrombocytopenia, and neutropenia as independent prognostic factors
for eligibility to CAR T cell therapy.

The study authors concluded that heavily treated patients with RRMM are likely to be eligible for CAR T cell therapy, and these
data could help to better define patients who could benefit from this approach.

WATCH WATCH
DR. REECE’S IN-DEPTH PRESENTATION OF THIS DR. REECE’S THOUGHTS ON THE RELEVANCE OF
ABSTRACT (~5 MINUTES) THESE DATA TO CANADIAN PRACTICE (~2 MINUTES)

CLICK HERE FOR THE LINK TO THE FULL ABSTRACT

Correlative Analysis to Define Patient Profiles Associated with Manufacturing and
Clinical Endpoints in Relapsed/Refractory Multiple Myeloma Patients Treated with
Idecabtagene Vicleucel (BB2121)

Rytlewski J, et al. Presented at EHA 2022 Congress. Abstract P866.

The BCMA-directed CAR T cell therapy ide-cel has demonstrated deep and durable responses in RRMM patients. The
objective of this analysis was to define patient profiles correlated with manufacturing and clinical endpoints in RRMM patients
treated with ide-cel in KarMMa and KarMMa-2 cohort 1 clinical trials using unsupervised clustering and multivariate machine
learning.

Peripheral blood mononuclear cell (PBMC) profile, in-process cell growth variables, and drug product variables were used
to define patient clusters, of which four were identified in 164 RRMM patients treated with ide-cel. The four patient clusters
showed significantly different PFS and response rates, with cluster 1 (poor manufacturing profiles) being the least favourable
with a median PFS of <3 months and complete response rate (CRR) <20%, and cluster 4 (better manufacturing endpoints)
being the most favourable with a longer median PFS of >14 months and a higher CRR of >60% (see Figure).

TABLE OF CONTENTS 9